

<b>LIST OF REFERENCES CITED BY APPLICANT</b> (Use several sheets if necessary)	ATTY. DOCKET NO. <b>10165-027-999</b>	APPLICATION NO. <b>10/676.694</b>
	APPLICANT <b>Brines et al.</b>	
	FILING DATE <b>September 30, 2003</b>	ART UNIT <b>1646</b>

<b>U.S. PATENT DOCUMENTS</b>					
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR

<b>FOREIGN PATENT DOCUMENTS</b>					
		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	B17	WO 02/000721	2/9/06	The Kenneth S. Warren Institute, Inc.; Lundbeck, H., A/S	T

<b>NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials		(Include name of the author (in CAPITAL LETTERS), Title, Date, Pertinent Pages, Etc.)	T
	C57	GORIO et al., 2002, "Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma," Proc. Nat. Acad. Sci. USA 99:9450-5	
	C58	CALVILLO et al., 2003, "Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling," Proc. Nat. Acad. Sci. USA 100:4802-6	

<b>EXAMINER</b> NY1-4221451v1	/Ruixiang Li/	<b>DATE CONSIDERED</b> 11/20/2009
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /R.L./**